S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

OrganiGram Stock Forecast, Price & News

-0.13 (-6.67%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
8.44 million shs
Average Volume
11.98 million shs
Market Capitalization
$545.71 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive OGI News and Ratings via Email

Sign-up to receive the latest news and ratings for OrganiGram and its competitors with MarketBeat's FREE daily newsletter.

OrganiGram logo

About OrganiGram

OrganiGram Holdings, Inc. engages in the production and sale of medical marijuana. It focuses on producing cannabis for patients and adult recreational consumers. The firm's brands include Adult Recreational and Medical. The company was founded on July 5, 2010 and is headquartered in Moncton, Canada.


OrganiGram (NASDAQ:OGI) Shares Down 5.6%
November 29, 2021 |  americanbankingnews.com
OrganiGram (OGI) Reports Q4 Loss, Tops Revenue Estimates
November 23, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$64.61 million
Cash Flow
$0.01 per share
Book Value
$1.15 per share


Net Income
$-101.29 million
Net Margins
Pretax Margin




Free Float
Market Cap
$545.71 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.71 out of 5 stars

Medical Sector

919th out of 1,390 stocks

Pharmaceutical Preparations Industry

434th out of 668 stocks

Analyst Opinion: 3.1Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

OrganiGram (NASDAQ:OGI) Frequently Asked Questions

Is OrganiGram a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OrganiGram stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OGI, but not buy additional shares or sell existing shares.
View analyst ratings for OrganiGram
or view top-rated stocks.

How has OrganiGram's stock been impacted by COVID-19 (Coronavirus)?

OrganiGram's stock was trading at $1.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OGI stock has increased by 5.8% and is now trading at $1.82.
View which stocks have been most impacted by COVID-19

Are investors shorting OrganiGram?

OrganiGram saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 17,300,000 shares, an increase of 28.1% from the October 31st total of 13,510,000 shares. Based on an average trading volume of 6,830,000 shares, the short-interest ratio is presently 2.5 days.
View OrganiGram's Short Interest

When is OrganiGram's next earnings date?

OrganiGram is scheduled to release its next quarterly earnings announcement on Tuesday, January 11th 2022.
View our earnings forecast for OrganiGram

How were OrganiGram's earnings last quarter?

OrganiGram Holdings Inc. (NASDAQ:OGI) issued its earnings results on Monday, July, 12th. The company reported ($0.01) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.03) by $0.02. The firm earned $16.55 million during the quarter, compared to the consensus estimate of $13.95 million. OrganiGram had a negative trailing twelve-month return on equity of 19.91% and a negative net margin of 190.24%.
View OrganiGram's earnings history

What price target have analysts set for OGI?

8 brokers have issued twelve-month price targets for OrganiGram's shares. Their forecasts range from $3.00 to $6.00. On average, they anticipate OrganiGram's share price to reach $4.04 in the next year. This suggests a possible upside of 121.7% from the stock's current price.
View analysts' price targets for OrganiGram
or view top-rated stocks among Wall Street analysts.

Who are OrganiGram's key executives?

OrganiGram's management team includes the following people:
  • Beena G. Goldenberg, Chief Executive Officer
  • Derrick W. West, Chief Financial Officer
  • Paolo de Luca, Chief Strategy Officer
  • Borna Zlamalik, Vice President-Innovation
  • Tim Emberg, Senior VP-Sales & Commercial Operations

What other stocks do shareholders of OrganiGram own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include KushCo (KSHB), (CGC), Auxly Cannabis Group (CBWTF), Supreme Cannabis (SPRWF), Medical Marijuana (MJNA), Cannabics Pharmaceuticals (CNBX), MariMed (MRMD), Aurora Cannabis (ACB), EVIO (EVIO) and Gran Tierra Energy (GTE).

What is OrganiGram's stock symbol?

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

Who are OrganiGram's major shareholders?

OrganiGram's stock is owned by many different retail and institutional investors. Top institutional investors include TD Asset Management Inc. (0.27%), Two Sigma Advisers LP (0.25%), Dimensional Fund Advisors LP (0.25%), Public Sector Pension Investment Board (0.21%), Penserra Capital Management LLC (0.21%) and Swiss National Bank (0.19%).

Which institutional investors are selling OrganiGram stock?

OGI stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Morgan Stanley, Millennium Management LLC, Deutsche Bank AG, Jump Financial LLC, Penserra Capital Management LLC, AdvisorShares Investments LLC, and UBS Group AG.

Which institutional investors are buying OrganiGram stock?

OGI stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Connor Clark & Lunn Investment Management Ltd., Two Sigma Advisers LP, Vontobel Holding Ltd., Goldman Sachs Group Inc., Swiss National Bank, HighTower Advisors LLC, and Public Sector Pension Investment Board.

How do I buy shares of OrganiGram?

Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OrganiGram's stock price today?

One share of OGI stock can currently be purchased for approximately $1.82.

How much money does OrganiGram make?

OrganiGram has a market capitalization of $545.71 million and generates $64.61 million in revenue each year. The company earns $-101.29 million in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does OrganiGram have?

OrganiGram employs 517 workers across the globe.

What is OrganiGram's official website?

The official website for OrganiGram is www.organigram.ca.

Where are OrganiGram's headquarters?

OrganiGram is headquartered at 35 English Dr., Moncton Z4, E1E 3X3.

How can I contact OrganiGram?

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at (844) 644-4726.

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.